HEPTA Medical

HEPTA Medical is a France-based Health Care startup founded in 2018 that aims to revolutionize the treatment of lung cancer. Their slogan, "Introducing a safe and early treatment of lung cancer.", succinctly captures their mission.

Their unique approach involves the development of a minimally invasive non-surgical treatment modality for early lung cancer. This innovation allows for real-time, targeted, and adapted ablation of the lesions. The significance of this endeavor cannot be overstated, given that lung cancer claims the lives of 2.1 million patients worldwide annually.

Recent results from the National Lung Screening Trial (NLST) have underscored the positive impact of lung screening programs on mortality, reshaping pulmonology practices. This paradigm shift has prompted technological advances geared towards modalities that integrate navigation, access, diagnosis, and on-the-spot treatment.

More specifically, HEPTA Medical is developing an endoscopically delivered ablation catheter that leverages temperature-based feedback and real-time dosing to precisely target and ablate pulmonary nodules, which are the precursors of lung cancer. Notably, this is achieved without the need for surgery or radiation.

Their most recent milestone was the Seed Round investment at 01 June 2019, with MD Start as the lead investor. This infusion of capital is not only a testament to the potential of HEPTA Medical but also underscores the confidence MD Start has in the promising trajectory of this forward-looking startup.